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Background: Alterations or mutations in the lipoprotein lipase (LPL) gene contribute to severe hypertriglyceridemia
(HTG). This study reported on two patients in a Chinese family with LPL gene mutations and severe HTG and acute
pancreatitis.
Methods: Two patients with other five family members were included in this study for DNA-sequences of
hyperlipidemia-related genes (such as LPL, APOC2, APOA5, LMF1, and GPIHBP1) and 43 healthy individuals
and 70 HTG subjects were included for the screening of LPL gene mutations.
Results: Both patients were found to have a compound heterozygote for a novel LPL gene mutation (L279V) and a
known mutation (A98T). Furthermore, one HTG subject out of 70 was found to carry this novel LPL L279V mutation.
Conclusions: The data from this study showed that compound heterozygote mutations of A98T and L279V
inactivate lipoprotein lipase enzymatic activity and contribute to severe HTG and acute pancreatitis in two Chinese
patients. Further study will investigate how these LPL gene mutations genetically inactivate the LPL enzyme.
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Lipoprotein lipase (LPL) is a member of the lipase gene
family, which includes lipases in the pancreas, liver, and
endothelium and plays a critical role in metabolism of
triglyceride (TG) by hydrolyzing TG-rich lipoprotein to
free fatty acids using apolipoprotein C-II (apoC-II) as a
cofactor. Alterations or mutations in the LPL gene could
result in massive accumulation of chylomicrons and
profound fasting hypertriglyceridemia (HTG) [1]. Patients
with severe HTG (TG > 11.3 mmol/l) usually suggest
genetic reasons and show clinical features of recurrent
attacks of pancreatitis, hepatosplenomegaly, lipemia reti-
nalis and eruptive xanthomas. The primary severe HTG
may be caused by gene mutations, including deficiency of
LPL, apoC-II and apoA-V, correspondingly to mutations
of LPL, APOC2, and APOA5 genes, respectively [2,3].
Recently, other two novel proteins were identified to be* Correspondence: hzmwenzhou@163.com
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unless otherwise stated.essential for proper LPL function, i.e., lipase maturation
factor1 (LMF1) and glycosylphosphatidylinositol-anchored
high-density lipoprotein-binding protein 1 (GPIHBP1);
thus, they are of importance for studying HTG [4,5],
although mutations of LPL gene are responsible for the
most common form of primary severe HTG.
Human LPL gene is composed of 10 exons and spans
approximately 30 kb on chromosome 8p22 encoding a
protein with 448 amino acids [6]. LPL gene mutations
include insertion, duplication, deletion, nonsense, frame-
shift, or missense mutations. Most LPL gene mutations-
caused LPL deficiency are due to missense mutations,
although other types of mutations have been previously
reported [7]. To date, there are over a hundred LPL gene
mutations reported in the literature to cause clinical
hyperchylomicronemia syndrome in the Human Gene
Mutation Database. In this study, we described a novel
LPL gene missense mutation (L279V) in two Chinese
patients with severe HTG and acute pancreatitis.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Subjects
In the present study, a 28-year-old female Han Chinese
with her first pregnancy during the third trimester was
admitted to our emergency room and diagnosed with acute
pancreatitis. Several days prior to this episode, lactescent
levels were elevated in her serum however this was not
noted. When admitted, blood tests revealed extremely high
serum levels of HTG (TG 79 mmol/l, while normal ranges
are 0.0-1.7 mmol/l). Following immediate cesarean section,
she gave birth to a healthy baby girl and then was treated
with dietary restriction and supportive treatment for
28 days, then discharged from the hospital.
Meanwhile, the 58-year-old mother was also admitted
to our hospital with a diagnosis of acute pancreatitis. In-
cluding this hospitalization, she had two previous epi-
sodes of abdominal pain and was diagnosed with acute
pancreatitis after intake of fatty food. The plasma levels
of total triglyceride were 25.4 and 16.3 mmol/l, respect-
ively at these episodes. The proband’ mother was mar-
ried to her father at age 22 through a consanguineous
marriage. Because these two patients presented with se-
vere HTG and acute pancreatitis, they were strongly
suggestive of an inherited condition.
Thus, we included not all but five of their family mem-
bers, i.e., the father, two aunts, one uncle and one sister
in our study. They all were shown to have mild hyperlip-
idemia but no history of diabetes mellitus, abdominal
pain or pancreatitis. In addition, we also recruited an
additional 43 healthy individuals and 70 unrelated HTG
subjects as controls for this study.
This study was approved by the Ethics Committee of
Wenzhou Medical University and signed informed consent
was obtained from all subjects participated in this study.
Measurement of plasma lipase and LPL mass and activity
Blood samples were collected into Na-EDTA tubes 15 min
following an intravenous heparin (60 IU/kg body weight)
injection in these patients and in 10 healthy controls,
including 5 men and 5 women after an overnight fast. LPL
enzyme activity in post-heparin treatment was measured
as described previously [8]. LPL mass was measured using
a sandwich-ELISA with a Human Lipoprotein Lipase
ELISA Kit (Nanjing Jiancheng, Nanjing, China).
Plasma lipid concentrations were also measured using
standardized enzymatic methods as described previously
[9]. The serum was diluted with saline solution (1:5)
before measurement of HDL-C due to the high TG con-
centration for the daughter.
PCR-amplification and DNA-Sequencing of candidate genes
Genomic DNA was extracted from 2 ml whole blood
samples using a Gentra Puregene Blood kit according
to the manufacturers’ instructions (Qiagen, Dusseldorf,Germany). All coding regions and the intron-exon bound-
aries of LPL (NM_000237), APOC2 (NM_000483), APOA5
(NM_052968), LMF1 (NM_022773), and GPIHBP1
(NM_178172) genes were PCR-amplified and bidirec-
tionally DNA-sequenced using the Sanger method based
on dideoxy chain-termination technology, as described
previously [10,11].
Screening for LPL gene mutations
The screening of the novel LPL variant L279V and the
known variant A98T were performed in 43 healthy individ-
uals and 70 HTG subjects using an i-plexGOLD genotyp-
ing assay of the MassARRAY mass-spectrometry system,
following the protocol recommended by the manufacturer
(Sequenom, Santiago, USA).
Species examination
We examined evolutionary conservation of the L279 amino
acid residue across various species from chimpanzee (a
close evolutionary relative) to wild goose and zebra fish
(both distant evolutionary counterparts).
Results
Genetic and biochemical features of the patients
Pedigree of the probands is shown in Figure 1. Muta-
tional analyses of the LPL, APOC2, APOA5, LMF1, and
GPIHBP1 genes showed that both patients had the same
compound heterozygote of the LPL gene for a novel mis-
sense mutation (L279V) and a known missense mutation
(A98T). One unrelated HTG patient was also found to be
heterozygote of the p.(L279V) variant. The novel missense
mutation L279V (p.L279V, rs371282890) at exon 6 is a
CTG→GTG change in codon 279 of the LPL gene, lead-
ing to L→ V amino acid substitution in the LPL pro-
tein (Figure 2).The known missense mutation of LPL
A98T (p.A98T, rs145657341) is a GCC→ ACC change
in codon 98 of the LPL gene, leading to an A→ T
amino acid substitution (Figure 3). The father (I3) was
found to be a carrier of L279V, while the uncle (I2), one
aunt (I5) and the elder sister (II3) were carriers of A98T.
I2, I5, I6 also have S447X mutations. There were no
mutations found in APOC2, APOA5, GPIHBP1 or LMF1.
LPL mutations and biochemical features of these two
patients and their family members are shown in Table 1.
However, in cross species comparison, we found that L279
residue is very conserved across the species (Figure 4).
Screening for LPL gene mutations in HTG subjects
Among the 70 unrelated HTG subjects, we found one
HTG subject who carried the L279V mutation. This
patient had an episode of acute pancreatitis and the TG
levels were 15.3 mmol/l. Thus, we further analyzed and
DNA-sequenced his genomic DNA for LPL, APOC2,
APOA5, LMF1 and GPIHBP1 genes. The data showed
Figure 1 Pedigree of the patient’s family. Black symbols represent the presence of a A98T mutation. Shaded symbols represent the presence of a
L279V mutation. The arrow indicates probands. Parental consanguinity is indicated by a double line. I 1, I 7, I 8 and II1 were not a part of the study.
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rs11538389) with heterozygosity of the gene. However, both
A98T and L279V mutations were not found in any healthy
individuals and other HTG subjects.
Detection of post-heparin LPL activity and mass levels in
patients and controls
We then detected post-heparin LPL activity and mass
levels in patients and controls and found that comparedFigure 2 DNA sequence of LPL gene exon 6 mutations.to normal controls, the post-heparin LPL activity of the
proband and her mother were reduced by 55.4% and
32.1%, respectively, although their plasma LPL mass was
close to the normal controls (data not shown).
Discussion
In the current study, we showed two-related patients who
manifested massive HTG and acute pancreatitis with a
low LPL post-heparin activity. Both probands present
the same LPL genotype with a compound heterozygote
for a known missense mutation A98T in exon3 and aFigure 3 DNA sequence of LPL gene exon 3 mutations.
Table 1 LPL mutations and biochemical features of the 2 probands and their family members
Subject Status Genotype Sex/age BMI
(kg/m2)
Plasma lipid levels (mmolL−1)
TC TG HDL-C LDL-C
I2 Uncle A98T/S447X M/69 24.2 5.36 4.53 1.02 1.78
I3 Father L279V M/63 23.5 5.13 2.03 1.21 1.53
I4 Mother(proband1) L279V/A98T F/58 19.2 7.99 16.33 0.54 1.28
I5 Niece A98T/S447X F/69 21.6 5.07 5.77 1.12 1.67
I6 Niece S447X F/66 20.1 5.72 5.45 1.36 2.06
II2 Daughter(proband2) L279V/A98T F/28 19.6 38.4 79.0 0.61 2.48
II3 Daughter A98T F/32 19.8 5.32 5.13 1.25 1.82
BMI, body mass index; TC, total cholesterol; TG, total triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
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Moreover, the novel mutation L279V was also found in
one of 70 HTG individuals.
To date, the majority disease-causing LPL gene muta-
tions occurs at exon 4, 5 and 6 residues (117–312), which
constitute a large N-terminal domain (residues 1–312)
of the enzyme and this region is the most conserved
and important for LPL catalytic functions [12]. Exon 6
(residues 232–313) encodes two structurally relevant
disulfide bridges (Cys278-Cys283 and Cys264-Cys275)
for the binding of heparin [13]. The novel mutation
L279V constitutes one of these two disulfide bridges
(Cys278-Cys283), which is important for catalytic function
of heparin binding. Both patients had low post-heparin
LPL activity but normal levels of mass, further demon-
strating this possibility.
Furthermore, we also assessed the L279V mutation
disease-causing potential by comparing it across various
species. We found that the L279 site is indeed conserved
throughout evolution from chimpanzee to zebra fish,
suggesting that this residue may play a critical role in
LPL function. In the current study, we found a total ofFigure 4 Comparison of evolutionary conservation of the L279
amino acid residue in various species.four carriers of L279V mutation including the two patients
and one family member, and an unrelated HTG individ-
ual, all of whom were heterozygotes for this missense
mutation. This novel LPL mutation (L279V) was sub-
mitted to NCBI and the Submitter SNP accession num-
ber is ss#550039488. In addition, the known LPL gene
mutation A98T has been described previously with lipo-
protein lipase deficiency in the clinic [14]. To date, there
were three family members found to carry this mutation,
one with a single mutation and others with compound
heterozygous for another nonsense mutation S447X of
LPL.
Patients with two defective LPL alleles will have no
or markedly reduced LPL activity, thus, homozygous or
compounds of heterozygous mutations lead to severe
HTG while one defective LPL allele may have normal to
moderately increased blood levels of fasting triglyceride
[15-17]. In this study, the mother and daughter had the
same LPL genotype with compound heterozygous mu-
tations of A98T and L279V; thus, both manifested
massive HTG and acute pancreatitis. In contrast, the
family members who carried a single mutation either
A98T or L279V, only presented mild HTG and had no
history of acute pancreatitis. Moreover, another unrelated
HTG individual, who had the compound heterozygote
L279V and a known GPIHBP1 mutation, suffered from a
severe HTG and acute pancreatitis.
In the current study, we found that two family members
had compound LPL gene A98T and S447X mutations, but
they also had mild elevated blood TG levels. The reason
for this is unclear, but may be because of the special muta-
tion S447X. In a previous study, LPL S447X mutation was
shown to have a naturally occurring gain-function [18].
This LPL mutation S447X is the only mutation that has a
protective effect against the development of HTG and cor-
onary heart disease by decreasing plasma TG levels in the
clinic and increasing HDL production [19]. Thus, gene
therapy using the S447X variant has shown therapeutic
promise in the study of LPL deficiency [20].
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